Australia’s CSL Prices Hemophilia Gene Therapy at $3.5M
Australian drugmaker CSL Ltd (CSL.AX), opens new tab on Tuesday set the list price of its one-time gene therapy for hemophilia B at $3.5 million, making it the world’s most expensive treatment, following its approval by the U.S. health regulator.
Australian drugmaker CSL Ltd (CSL.AX), opens new tab on Tuesday set the list price of its one-time gene therapy for hemophilia B at $3.5 million, making it the world’s most expensive treatment, following its approval by the U.S. health regulator.
